

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Alliance HealthCare Services, Inc. 2. 18201 Von Karman Ave. STE 600 Irvine, CA 92612		In accordance with letter dated February 11, 2022, 3. License No.: 47-25570-01 is amended in its entirety to read as follows:	4. Expiration Date: November 30, 2036 5. Docket No.: 030-35774 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.200 B. Strontium-82 C. Strontium-85 D. Germanium-68	7. Chemical and/or physical form A. Any B. Any Except Sealed Sources C. Any Except Sealed Sources D. Sealed Sources	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. 200 millicuries total C. 1 curie total D. 50 millicuries total	9. Authorized use A. For use in imaging and localization studies permitted by 10 CFR 35.200. B. For decay in storage only in accordance with 10 CFR 35.92. C. For decay in storage only in accordance with 10 CFR 35.92. D. For storage only, limited to one year, incident to transfer in accordance with 10 CFR 30.41.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Amendment No. 33

Docket or Reference No.:
030-35774**CONDITIONS**

10. A. Licensed material listed in Subitem No. 6.A. incident to mobile nuclear medicine activities shall be used or stored at temporary job sites of the licensee anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States.

If the jurisdiction status of a Federal facility within an Agreement State is unknown, the licensee should contact the Federal agency controlling the job site in question to determine whether the proposed job site is an area of exclusive Federal jurisdiction. Authorization for use of radioactive materials at job sites in Agreement States not under exclusive Federal jurisdiction shall be obtained from the appropriate state regulatory agency.

- B. Licensed material listed in Subitem Nos. 6.B and 6.C., limited to strontium waste generated incident to mobile nuclear medicine activities, shall be stored at the licensee's facilities located at 525 S Gould St., Owosso, Michigan, for decay in storage in accordance with 10 CFR 35.92.
- C. Licensed material listed in Subitem No. 6.D., limited to germanium-68 sealed sources transferred from the licensee's mobile nuclear medicine vans, shall be stored at the licensee's facilities located at 525 S. Gould Street, Owosso, Michigan, for up to one year pending transfer to an authorized recipient in accordance with 10 CFR 30.41.
11. The Radiation Safety Officer for this license is Kay Kassel, M.S., C.N.M.T.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u> |
|---|-------------------------|
| David Abramowitz, M.D. | 10 CFR 35.200 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Docket or Reference No.:
030-35774

Amendment No. 33

Authorized User (M.D., D.O., etc.)Material and Use

Jennifer Jayne Adams, M.D.

10 CFR 35.200

Irfan Ahmad, M.D.

10 CFR 35.200

Afzal Ahmed, M.D.

10 CFR 35.200

Mark J. Akers, M.D.

10 CFR 35.200

Paul D. Akers, M.D.

10 CFR 35.200

Syed I. Ali, M.D.

10 CFR 35.200

Rajaa M. Almestady, M.D.

10 CFR 35.200

Daniel Altman, M.D.

10 CFR 35.200

Marsha Anderson, M.D.

10 CFR 35.200

Mark C. Arvin, M.D.

10 CFR 35.200

Akhtar Ashraf, M.D.

10 CFR 35.200

James Baek, M.D.

10 CFR 35.200

Indraneel Banerji, M.D.

10 CFR 35.200

David Bauer, M.D.

10 CFR 35.200

James R. Bergh, M.D.

10 CFR 35.200

Richard R. Black, D.O.

10 CFR 35.200

Rodger Blake, M.D.

10 CFR 35.200

Paul Henry Blom, M.D.

10 CFR 35.200

Suzanne Bosman, M.D.

10 CFR 35.200

Joel A. Brake, M.D.

10 CFR 35.200

James M. Browne, M.D.

10 CFR 35.200

Douglas A. Bruns, D.O.

10 CFR 35.200

David J. Burkart, M.D.

10 CFR 35.200

Jeffery S. Cahoon, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Docket or Reference No.:
030-35774

Amendment No. 33

Authorized User (M.D., D.O., etc.)Material and Use

James Paul Carl, M.D.

10 CFR 35.200

Peter Chirico, M.D.

10 CFR 35.200

Corey W. Chopra, M.D.

10 CFR 35.200

Jesse A. Cole, M.D.

10 CFR 35.200

Ricky J. Compton, M.D.

10 CFR 35.200

John Phillip Cox, D.O.

10 CFR 35.200

Robert J. Cure, M.D.

10 CFR 35.200

Anthony R. D'Amico, M.D.

10 CFR 35.200

Ryan Daily, M.D.

10 CFR 35.200

Kyle L. Dale, M.D.

10 CFR 35.200

Daniel J. Daunhauer, M.D.

10 CFR 35.200

Peerawut Deeprasertkul, M.D.

10 CFR 35.200

Vu Quoc Do, M.D.

10 CFR 35.200

Sarsfield Patrick Dougherty, M.D.

10 CFR 35.200

Hans G. Dransfeld, M.D.

10 CFR 35.200

Joseph W. Dransfeld, M.D.

10 CFR 35.200

Nathaniel D. Dueker, M.D.

10 CFR 35.200

Douglas M. Dunco, M.D.

10 CFR 35.200

Rodney A. Dunseath, D.O.

10 CFR 35.200

Paul H. Eikens, M.D.

10 CFR 35.200

Mark W. Elliott, M.D.

10 CFR 35.200

Susannah G. Ellsworth, M.D.

10 CFR 35.200

Adwoa Essel, M.D.

10 CFR 35.200

Hilary Ann Evans, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Docket or Reference No.:
030-35774

Amendment No. 33

Authorized User (M.D., D.O., etc.)Material and Use

Thomas H. Farquhar, M.D., Ph.D.

10 CFR 35.200

Angelo Steven Ferraro, M.D.

10 CFR 35.200

Luke Gerges, D.O.

10 CFR 35.200

Joshua Dale Gibson, M.D.

10 CFR 35.200

Kendall Goldschmidt, M.D.

10 CFR 35.200

Lee Corey Haikal, M.D.

10 CFR 35.200

Nathan R. Hatfield, M.D.

10 CFR 35.200

David Damion Hazlett, Jr., M.D.

10 CFR 35.200

Jeffrey A. Hicklin, M.D.

10 CFR 35.200

Robert Hills, D.O.

10 CFR 35.200

John Holmen, M.D.

10 CFR 35.200

Leszek J. Jaszczak, M.D.

10 CFR 35.200

Ronald D. Jenkins, M.D.

10 CFR 35.200

John Kalabat, M.D.

10 CFR 35.200

Craig S. Kamen, M.D.

10 CFR 35.200

Prasanta K. Karak, M.D.

10 CFR 35.200

Kevin Matthew Kavanaugh, M.D.

10 CFR 35.200

Jeffrey Kaye, M.D.

10 CFR 35.200

Imran Kazem, M.D.

10 CFR 35.200

Stephen Joowhan Kim, M.D.

10 CFR 35.200

Philip Kohanski, M.D.

10 CFR 35.200

Kenneth L. Koontz, M.D.

10 CFR 35.200

Michael V. Korona, Jr., M.D.

10 CFR 35.200

Gary W. Kravetz, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Docket or Reference No.:
030-35774

Amendment No. 33

Authorized User (M.D., D.O., etc.)Material and Use

Adam Thomas Krompecher, M.D.

10 CFR 35.200

Francisco J. Lammoglia, M.D.

10 CFR 35.200

Christopher J. Leary, M.D.

10 CFR 35.200

Terry S. Lee, M.D.

10 CFR 35.200

Eric L. Leonard, M.D.

10 CFR 35.200

Donald Lewis, M.D.

10 CFR 35.200

Edward J. Maas, M.D.

10 CFR 35.200

Colleen M. Madden, M.D.

10 CFR 35.200

Mrinal Mali, M.D.

10 CFR 35.200

Michael J. Malnofski, M.D.

10 CFR 35.200

A. Jane MaLoof, M.D.

10 CFR 35.200

Jack D. Markiewicz, M.D.

10 CFR 35.200

Phyllis Martin-Simmerman, M.D.

10 CFR 35.200

William Mason, M.D.

10 CFR 35.200

Matthew E. Maxwell, M.D.

10 CFR 35.200

Marco S. Mazzella, M.D.

10 CFR 35.200

Elvin McCarl, M.D.

10 CFR 35.200

Andrew T. Miller, M.D.

10 CFR 35.200

Richard D. Miller, M.D.

10 CFR 35.200

Steve Min, D.O.

10 CFR 35.200

Virginia Molleran, M.D.

10 CFR 35.200

Craig Moore, M.D.

10 CFR 35.200

Joshua A. Nepute, M.D.

10 CFR 35.200

Josef R.S. Noga, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Docket or Reference No.:
030-35774

Amendment No. 33

Authorized User (M.D., D.O., etc.)Material and Use

Kevin O'Brien, M.D.
Patrick M. O'Toole, M.D.
Dana Olson, M.D.
Robert Oostveen, M.D.
Samir Parikh, M.D.
Bharat Patel, M.D.
Grant D. Petty, M.D.
Krishna R. Pillai, M.D.
James Milton Reynolds, M.D.
Reuben Rock, M.D.
Daniel Adam Rodgers, M.D.
Colin Rose, M.D.
Heather Rose, M.D.
Ronald J. Rosenberg, M.D.
Aldo Ruffolo, M.D.
Paul Sanchirico, M.D.
Mark Shaman, M.D.
Paul W. Sheets, M.D.
Steven K. Shekut, M.D.
Charles W. Siegler, M.D.
Justin Sims, M.D.
Stacy L. Spooner, M.D.
Gregory R. Spurling, M.D.
Michael A. Stewart, M.D.

10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200
10 CFR 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Docket or Reference No.:
030-35774

Amendment No. 33

Authorized User (M.D., D.O., etc.)Material and Use

LeAnn Stidham, M.D.

10 CFR 35.200

Nathan M. Strabala, M.D.

10 CFR 35.200

Edward Strauss, M.D.

10 CFR 35.200

Victoria A. Swegles, D.O.

10 CFR 35.200

Sanjay J. Talati, M.D.

10 CFR 35.200

Shrey K. Thawait, M.D.

10 CFR 35.200

Smari Thordarson, M.D.

10 CFR 35.200

Walter Parke Thrush, M.D.

10 CFR 35.200

Paul E. Timperman, M.D.

10 CFR 35.200

Gregory T. Turner, M.D.

10 CFR 35.200

Torin P. Walters, M.D.

10 CFR 35.200

James K. Watson, M.D.

10 CFR 35.200

Ronald R. Weis, M.D.

10 CFR 35.200

Jonathan W. Weiss, M.D.

10 CFR 35.200

Michael Whisenant, M.D.

10 CFR 35.200

Thomas T. Win, M.D.

10 CFR 35.200

Milton R. Wolf, M.D.

10 CFR 35.200

Ehab H. Youssef, M.D.

10 CFR 35.200

John S. Yungmeyer, M.D.

10 CFR 35.200

Roy W. "Chip" Zimmer, III, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Docket or Reference No.:
030-35774

Amendment No. 33

C. The following individuals are authorized users for nonmedical uses as indicated:

Non-Medical Use

Kay Kassel, M.S., C.N.M.T.

Material and Use

Strontium-82/85 for decay-in-storage; Germanium-68 sealed sources for storage only

13. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
14. Sealed sources containing licensed material shall not be opened by the licensee, except as specifically authorized.
15. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months, or at such other intervals as specified.
- B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
- D. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-25570-01

Amendment No. 33

Docket or Reference No.:
030-35774

- E. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
- F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- G. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for 3 years.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 47-25570-01

Amendment No. 33

Docket or Reference No.:
030-35774

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Letter, Application, and Delegation of Authority dated June 3, 2021, excluding Radiation Safety Program policies and procedures (ML21172A247)
- B. Letter dated July 6, 2021 (ML21197A087)
- C. Letter dated October 18, 2021 (ML21299A298)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: April 15, 2022By: _____
Magdalena R. Gryglak
Region 3